MyPath Melanoma reposted this
#ASDS2024 was amazing! Our team enjoyed connecting with others and sharing how our tests, DecisionDx-SCC, DecisionDx-Melanoma, and MyPath Melanoma, can improve manage patient care.
Diagnostic GEP testing is intended to aid in the characterization of primary cutaneous lesions with uncertain malignant potential. Test results should be interpreted in the context of other clinical, laboratory, and histopathological findings.
External link for MyPath Melanoma
MyPath Melanoma reposted this
#ASDS2024 was amazing! Our team enjoyed connecting with others and sharing how our tests, DecisionDx-SCC, DecisionDx-Melanoma, and MyPath Melanoma, can improve manage patient care.
NOW PUBLISHED: two recent studies published in the Journal of Cutaneous Pathology and Melanoma Management provide further support for the clinical need of Castle's MyPath® Melanoma gene expression profile (GEP) test, designed to aid in providing an accurate diagnosis for ambiguous melanocytic lesions of uncertain malignant potential. The studies demonstrate the significant disagreement that exists in the diagnosis of melanocytic lesions using pathology alone, the variability of surgical management of lesions among treating dermatologists, and the risk-aligned changes and confidence in these decisions that can result from GEP testing. Highlights: https://hubs.la/Q02TK8090
Are you in Maui attending Dermatopathology in Paradise? We hope to see you at our product theater this afternoon! Castle Biosciences, Inc. #mypathmelanoma #GEPtesting
Castle Biosciences, Inc. is off to Maui Derm this weekend! Are you joining us?
MyPath Melanoma reposted this
Want to know what the dermatology lab process looks like at Castle? Join us for a behind-the-scenes tour of our Phoenix laboratory, and follow along from sample receipt to the generation of a test report. Empowering people. Informing care decisions. #DecisionDxMelanoma #DecisionDxSCC #MyPathMelanoma
If you missed this week's episode of Cases with Castle featuring Dr. Witkowski, don't worry - you can catch the replay here: https://hubs.la/Q02DB2Lb0. #caseswithcastle #genetictesting #melanoma Castle Biosciences, Inc.
Mark your calendar for a new Cases with Castle "GEP testing to achieve clinicopathological correlation in ambiguous melanocytic lesions" presented by Dr. Alexander Witkowski. Register today: https://lnkd.in/eVrzfGwY